Review



cd69 vioblue  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd69 vioblue
    Cd69 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 89 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human%2C+REAfinity/10__3389_slash_fimmu__2026__1844781-143-30-32
    Average 93 stars, based on 89 article reviews
    cd69 vioblue - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: T-cell responses shape infant SIV reservoirs and post-intervention control following AAV9-eCD4-Ig and latency reversal.
    Article Snippet: CD14 (M5E2), all BioLegend. Surface: CD3 (APC-Cy7, SP34-2; BD), CD4 (BV785, OKT4; 1425 BioLegend), CD8α (BV711, SK1; BioLegend), CD95 (BV605, DX2; BioLegend). AIM assay: CD25 1426 (PE-Vio770, REA570; Miltenyi), CD69 (BV421, FN50; BioLegend), OX40 (PE, L106; BD), 4-1BB 1427 (APC, REA765; Miltenyi). ICS assay: CD107a (VioBlue, H4A3; Miltenyi), IFN-γ (PE, 4S.B3; 1428 BioLegend), TNF-α (BV650, MAb11;



    Similar Products

    cd69 vioblue  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd69 vioblue
    Cd69 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human%2C+REAfinity/10__3389_slash_fimmu__2026__1844781-143-30-32
    Average 93 stars, based on 1 article reviews
    cd69 vioblue - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    cd69  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd69
    Cd69, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human%2C+REAfinity/pm42455847-67-100-102
    Average 93 stars, based on 1 article reviews
    cd69 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    cd69 antibody, anti-human, reafinity  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd69 antibody, anti-human, reafinity
    Cd69 Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human%2C+REAfinity/custom%40130-124-326%4042447860
    Average 93 stars, based on 1 article reviews
    cd69 antibody, anti-human, reafinity - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    cd69 antibody, anti-human  (Miltenyi Biotec)
    94
    Miltenyi Biotec cd69 antibody, anti-human
    Cd69 Antibody, Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human/custom%40130-108-065%4042314934
    Average 94 stars, based on 1 article reviews
    cd69 antibody, anti-human - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti human cd69  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti human cd69
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Human Cd69, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human/pmc13314487-83-41-43
    Average 94 stars, based on 1 article reviews
    anti human cd69 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti cd69 apc vio 770  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti cd69 apc vio 770
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Cd69 Apc Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/KIR2D+Antibody%2C+anti-human%2C+REAfinity/pmc13236643-54-38-53
    Average 94 stars, based on 1 article reviews
    anti cd69 apc vio 770 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti human cd69 fitc  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti human cd69 fitc
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Human Cd69 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD69+Antibody%2C+anti-human/pmc13006415-64-0-3
    Average 94 stars, based on 1 article reviews
    anti human cd69 fitc - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti cd69  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti cd69
    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) <t>CD69</t> + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.
    Anti Cd69, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd69+antibody%2C+anti-human/CD274+(B7-H1)+Antibody%2C+anti-human%2C+REAfinity/pm41840113-195-30-43
    Average 94 stars, based on 1 article reviews
    anti cd69 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: Characterization of CD8 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis showing cell percentage of (a, g) CD8 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + in peripheral blood mononuclear cells (PBMCs) of (a-f) IFN- and (g-l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Flow Cytometry

    Evaluation of CD4 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Percentage of (a, g) CD4 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + cells in peripheral blood mononuclear cells (PBMCs) of (a, f) IFN- and (g, l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: Evaluation of CD4 + cells in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Percentage of (a, g) CD4 + , (b, h) CD154 + , (c, i) CD69 + , (d, j) OX40 + , (e, k) TIGIT + , (f, l) CD62L + cells in peripheral blood mononuclear cells (PBMCs) of (a, f) IFN- and (g, l) OCRE-treated pwMS before (T0), 21 days after the first (T1) and the second (T2) vaccine dose. (a-f) IFN: T0: n=10; T1: n=10; T2: n= 10; (g-l) OCRE: T0: n=10; T1: n=10; T2: n= 9. Each data point represents a distinct individual (i.e., an independent biological sample). Data are presented as median values. Statistical analysis was performed by using the Wilcoxon signed-rank test (two tails); * p ≤ 0.05; ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques:

    T cell comparison in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Fold change over basal [calculated as the ratio between the percentage of cells at T1 and T2 compared to baseline (T0)] of (a) CD8 + , (b) CD154 + , (c) CD69 + , (d) OX40 + , (e) TIGIT + , (f) CD62L + and (g) CD4 + , (h) CD154 + , (i) CD69 + , (j) OX40 + , (k) TIGIT + , (l) CD62L + cells in IFN (●) and OCRE (▲) -treated pwMS. Data are presented as median values. Statistical analysis was performed by using the Kruskal-Wallis test. * p ≤ 0.05, ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: T cell comparison in IFN- and OCRE-treated patients with multiple sclerosis (pwMS) undergoing BNT162b2 mRNA SARS-CoV-2 vaccination. Fold change over basal [calculated as the ratio between the percentage of cells at T1 and T2 compared to baseline (T0)] of (a) CD8 + , (b) CD154 + , (c) CD69 + , (d) OX40 + , (e) TIGIT + , (f) CD62L + and (g) CD4 + , (h) CD154 + , (i) CD69 + , (j) OX40 + , (k) TIGIT + , (l) CD62L + cells in IFN (●) and OCRE (▲) -treated pwMS. Data are presented as median values. Statistical analysis was performed by using the Kruskal-Wallis test. * p ≤ 0.05, ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Comparison

    CD8 + and CD4 + T cell response in INF-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) INF-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=4 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: CD8 + and CD4 + T cell response in INF-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) INF-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=4 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Flow Cytometry, Sequencing, MANN-WHITNEY

    CD8 + and CD4 + T cell response in OCRE-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) IFN-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=3 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Journal: Frontiers in Immunology

    Article Title: Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

    doi: 10.3389/fimmu.2026.1773417

    Figure Lengend Snippet: CD8 + and CD4 + T cell response in OCRE-treated patients with multiple sclerosis (pwMS) before and after BNT162b2 mRNA SARS-CoV-2 vaccination. Cumulative data of flow cytometry analysis of spike-specific CD8 + and CD4 + T cells measured as the percentage of activated (a) CD69 + CD137 + and (d) CD154 + OX40 + T cells, respectively. Intracellular cytokines evaluation of (b) IFN-γ and (c) TNF-α in CD8 + antigen-specific T cells and (e) IFN-γ, (f) TNF-α, and (g) IL-2 in CD4 + antigen-specific T cells. Analysis was performed after stimulation for 18 hours at 37 °C with a peptide pool spanning the entire Spike sequence. Data are presented as median values of at least n=3 subjects. Statistical analysis was performed by using the Mann-Whitney U -test (two tails); * p ≤ 0.05, ** p ≤ 0.01.

    Article Snippet: After the stimulation, cells were washed and surface stained for 20 minutes at 4 °C with the following antibodies: BV510-conjugated anti-human CD3 (Miltenyi, clone: BW264/56), APC-conjugated anti-human CD134 (OX40) (BD Pharmigen, clone: ACT35), APC-H7-conjugated anti-human CD4 (BD Pharmigen, clone: RPA-T4), PE-conjugated anti-human CD69 (Miltenyi, clone: FN50), PE-Cy 7-conjugated anti-human CD8 (BD Horizon, clone: RPA-T8).

    Techniques: Flow Cytometry, Sequencing, MANN-WHITNEY